TECregen
Latest round
- Seed
Last raised
- Jan 2026
Total raised
- $13M
Investors
- 7
About TECregen
Based in Basel, Switzerland, and founded in 2024 by Georg Hollander, Filippo Oliveri, and Ignacio Moraga, TECregen AG, focuses on creating advanced therapies to enhance immune function. As of January 2026, Klaas P. Zuideveld is the Chief Executive Officer (CEO) of the company. TECregen specializes in the development and commercialization of innovative thymopoietic therapies aimed at regenerating the thymus and restoring immune balance. Their core product offerings focus on precision-engineered biologics that leverage advanced ligand engineering, targeted delivery systems, and functional screening, resulting in tailored therapeutics designed to combat immune decline, cancer, and inflammatory diseases. The company's solutions are intended for healthcare providers and research institutions engaged in immunology and regenerative medicine, particularly targeting populations affected by compromised immune systems. TECregen’s products have been introduced to various international markets, aiming to serve patients and healthcare practitioners in North America, Europe, and Asia, addressing a growing demand for effective immune restoration therapies. TECregen's revenue model is primarily structured around partnerships with healthcare providers and research institutions, emphasizing B2B transactions. The company engages in collaborations that facilitate the delivery of its regenerative therapies, incorporating contractual agreements that outline the terms for product supply and distribution. Specific pricing plans for TECregen's offerings have not been disclosed; however, the company establishes pricing based on the unique characteristics of its flagship thymopoietic products and the needs of healthcare clients. Revenue generation is anticipated through direct sales to healthcare facilities and potential licensing agreements with pharmaceutical companies aiming to integrate TECregen's technologies into broader therapeutic applications.
Who invested in TECregen
7 investors across 1 round
See all investors in TECregen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jan 8, 2026
Amount
$13M
Investors
Questions about TECregen
Who invested in TECregen?
TECregen has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TECregen raised?
TECregen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TECregen last raise money?
TECregen's most recent round on record is a Seed, in Jan 2026.
What does TECregen do?
Based in Basel, Switzerland, and founded in 2024 by Georg Hollander, Filippo Oliveri, and Ignacio Moraga, TECregen AG, focuses on creating advanced therapies to enhance immune function.
Where is TECregen headquartered?
TECregen is headquartered in Basel, Switzerland.
Which VCs invest in companies like TECregen?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at TECregen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like TECregen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.